Skip to content
Nonprofiteer
← SOLVING KIDS CANCER INC

Form 990 for tax year 2022

Filed by SOLVING KIDS CANCER INC.

Totals

Total revenue
$894,267
Total expenses
$1,209,405
Contributions and grants received
$970,445
Grants paid
$536,079
Program service revenue
$0
Investment income
$25,663
Other revenue
-$101,841
Total assets, end of year
$2,595,479
Total liabilities, end of year
$152,179
Net assets or fund balances, end of year
$2,443,300
Program services expenses (Part IX)
$832,355
Management and general expenses
$135,786
Fundraising expenses
$241,264
Program service expenses (Part III)
$832,355

Program services were 68.8% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1c · Fundraising events

    $371,877

  • 1f · All other contributions, gifts and grants

    $598,568

  • 3 · Investment income

    total $25,663 · excluded $25,663

  • 8a · Fundraising events: gross income

    $56,200

  • 8a · Fundraising events: contributions included on line 1c

    $371,877

  • 8b · Fundraising events: direct expenses

    $158,041

  • 8c · Net income from fundraising events

    total -$101,841 · excluded -$101,841

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $469,734 · program services $469,734

  • 2 · Grants to domestic individuals

    total $15,650 · program services $15,650

  • 3 · Grants to foreign organizations and individuals

    total $50,695 · program services $50,695

  • 5 · Compensation of officers, directors and key employees

    total $159,521 · program services $76,907 · management and general $40,277 · fundraising $42,337

  • 7 · Other salaries and wages

    total $254,064 · program services $114,742 · management and general $70,747 · fundraising $68,575

  • 9 · Other employee benefits

    total $20,915 · program services $14,426 · management and general $1,582 · fundraising $4,907

  • 10 · Payroll taxes

    total $29,212 · program services $18,151 · management and general $1,110 · fundraising $9,951

  • 11c · Fees: accounting

    total $42,570 · program services $20,543 · management and general $6,569 · fundraising $15,458

  • 11e · Fees: professional fundraising services

    total $63,253 · fundraising $63,253

  • 11g · Fees: other

    total $31,997 · program services $15,380 · management and general $4,919 · fundraising $11,698

  • 12 · Advertising and promotion

    total $8,614 · program services $4,156 · management and general $1,330 · fundraising $3,128

  • 13 · Office expenses

    total $2,308 · program services $1,272 · management and general $309 · fundraising $727

  • 14 · Information technology

    total $5,487 · program services $2,646 · management and general $847 · fundraising $1,994

  • 16 · Occupancy

    total $28,042 · program services $13,531 · management and general $4,328 · fundraising $10,183

  • 17 · Travel

    total $6,854 · program services $4,624 · management and general $665 · fundraising $1,565

  • 23 · Insurance

    total $5,867 · program services $2,832 · management and general $905 · fundraising $2,130

  • 24a · Other expenses: DUES AND SUBSCRIPTIONS

    total $10,032 · program services $4,841 · management and general $1,548 · fundraising $3,643

  • 24b · Other expenses: MISCELLANEOUS

    total $2,902 · program services $1,401 · management and general $447 · fundraising $1,054

  • 24c · Other expenses: MEALS AND ENTERTAINMENT

    total $1,688 · program services $824 · management and general $203 · fundraising $661

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $380,203 · end of year $573,869

  • 2 · Savings and temporary cash investments

    beginning of year $2,314,177 · end of year $1,773,840

  • 3 · Pledges and grants receivable

    beginning of year $69,307 · end of year $93,245

  • 9 · Prepaid expenses and deferred charges

    beginning of year $7,027 · end of year $5,804

  • 15 · Other assets

    beginning of year $3,585 · end of year $148,721

  • 17 · Accounts payable and accrued expenses

    beginning of year $15,861 · end of year $4,926

  • 25 · Other liabilities

    beginning of year $0 · end of year $147,253

  • 27 · Net assets without donor restrictions

    beginning of year $868,512 · end of year $726,840

  • 28 · Net assets with donor restrictions

    beginning of year $1,889,926 · end of year $1,716,460

Mission and programs · 2022

Mission

SKC IMPACTS CHILDREN THROUGH THE INITIATION OF CLINICAL RESEARCH TRIALS OF INVESTIGATIONAL TREATMENT STRATEGIES. OUR VISION IS TO CONTINUE EXPANDING THE ARMAMENTARIUM OF EFFECTIVE AND LESS TOXIC TREATMENT STRATEGIES FOR PEDIATRIC ONCOLOGISTS TO UTILIZE UNTIL LONG-TERM SURVIVAL IS A REALITY FOR ALL CHILDREN WITH HIGH-RISK SOLID TUMORS AND BRAIN TUMORS.TO ACCOMPLISH OUR MISSION, SOLVING KIDS' CANCER FINDS, FUNDS AND ADVOCATES FOR BREAKTHROUGH TREATMENT OPTIONS TO CURE CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS THROUGH COLLABORATIVE PARTNERSHIPS WITH THE RESEARCH COMMUNITY AND RELATED NONPROFIT STAKEHOLDERS.

Activities or mission (Part I)

MAKE RADICAL IMPROVEMENTS IN SURVIVAL OUTCOMES FOR CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS USING A PATIENT-CENTRIC APPROACH OF DRIVING/SUPPORTING HIGH-IMPACT CLINICAL RESEARCH, PRECLINICAL THERAPEUTIC DEVELOPMENT PROJECTS, CONDUCTING RESEARCH ADVOCACY IN THE LANDSCAPE AND EMPOWERING FAMILIES WITH RESOURCES/TOOLS TO HELP THEM NAVIGATE TREATMENT OPTIONS FOR THEIR CHILD.

  • SKC AND OUR ADVISORS SURVEY, ACTIVELY DISCUSS AND PRIORITIZE THE AREAS OF GREATEST UNMET NEEDS WITHIN THE PEDIATRIC CANCER RESEARCH LANDSCAPE AND DEVELOP SPECIFIC PROGRAMS TO ADDRESS THEM. (1) THE PH I TITAN CLINICAL TRIAL IS PROVIDING AN EFFECTIVE TARGETED DRUG FOR CHILDREN WITH ALK MUTATIONS IN FRONTLINE TREATMENT WHEN NEWLY DIAGNOSED AND IS GENERATING CRITICAL DATA TOWARDS AN APPROVAL FOR USE AS A STANDARD OF CARE. WORKING TOWARDS HAVING THIS BE ONE OF THE FIRST TARGETED AGENTS BECOMING APPROVED FOR HR NB AND UTILIZED AS A COMBINATION THERAPY STRATEGY, MAKING A SIGNIFICANT IMPACT ON OVERALL SURVIVAL. (2) OUR COLLABORATION WITH THE NATIONAL CANCER INSTITUTE (NCI) TO VALIDATE AND DEVELOP AN IMMUNOTHERAPY TREATMENT FOR CHILDREN WITH ETMR BRAIN TUMORS USING A T-CELL CAR TO TARGET (CONTINUED ON SCH O) GPC2 IS THE FIRST-EVER IMMUNOTHERAPY RESEARCH PROGRAM SPECIFIC FOR ETMR BRAIN TUMORS. IF THE RESULTS ARE POSITIVE, THIS WORK WILL BE RAPIDLY TRANSLATED TO INCLUDE CHILDREN WITH ETMR IN A CLINICAL TRIAL USING THIS CUTTING-EDGE IMMUNOTHERAPY. (3) THE PH I CLIN TRIAL USING A TRIPLET COMBINATION HAS BEEN A LIFELINE FOR CHILDREN WITH NEUROBLASTOMA WHO RELAPSE AND THE STUDY HAS BEEN SO SUCCESSFUL THAT IT WILL STAY OPEN TO ACCRUE EVEN MORE PATIENTS THAN ORIGINALLY PLANNED. WHILE THE CLINICAL TRIAL IS PROVIDING TREATMENT BENEFIT TO PATIENTS, THE TRIAL IS GENERATING VERY IMPORTANT DATA THAT CAN BE USED TO FURTHER ADVANCE THIS TRIPLE TREATMENT COMBINATION INTO MORE POINTS IN THE TREATMENT CONTINUUM FOR EVEN GREATER PATIENT BENEFIT. (4) SKC TARGETS ONLY THE MOST CHALLENGING AND POOREST OUTCOME CHILDHOOD CANCERS THAT REQUIRE SIGNIFICANT HELP AND HAVE THE GREATEST UNMET NEED INCLUDING HIGH-RISK BRAIN TUMORS AND SOLID TUMORS. (5) TAKES A GLOBAL APPROACH TO SUPPORTING PROGRAMS TO LEVERAGE THE COLLECTIVE POWER OF COLLABORATION ACROSS SEVERAL CENTERS-OF-EXCELLENCE TO BREAK DOWN BARRIERS, SPEED PROGRESS AND HAVE MORE CHILDREN ACCESS PROMISING TREATMENTS. (6) PRIORITIZES ADVANCING TREATMENT OPTIONS THAT HAVE THE HIGHEST POTENTIAL FOR CURATIVE RESPONSES RATHER THAN PARTIAL TUMOR SHRINKAGE OR TEMPORARY LIFE EXTENSION. (7) TAKES LEADERSHIP ROLES WITHIN INFLUENTIAL NATIONAL AND INTERNATIONAL RESEARCH GROUPS' ADVISORY BOARDS AND CO-AUTHOR INFLUENTIAL PAPERS IN PROFESSIONAL JOURNALS TO DRIVE NEW DIRECTION TO POSITIVELY IMPACT PATIENTS. (8) BUILD COALITIONS AND PARTNERSHIPS WITH OTHER NONPROFITS IN COLLABORATIVELY DRIVING AND FUNDING RESEARCH PROJECTS FOR GREATER IMPACT AND SCALE BECAUSE WE ARE MUCH MORE EFFECTIVE TOGETHER THAN WORKING ALONE. SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE, NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY {VACCINES, CELLULAR THERAPY, ONCOLYTIC VIROTHERAPY, THERAPEUTIC ANTIBODIES, CHECKPOINT INHIBITORS}, SYNERGISTIC COMBINATION TREATMENTS, NEW GENOMICALLY TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TOXIC TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARE. (9) WE ARE PLANNING A NEW INITIATIVE FOR MEDULLOBLASTOMA TO IDENTIFY PROMISING COMBINATION THERAPIES THAT CROSS THE BLOOD-BRAIN BARRIER AS WELL AS NEW DELIVERY MECHANISMS.

    Expenses $832,355 · Grants $536,079

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Scott Kennedy

    EXECUTIVE DIRECTOR, CO-FOUNDER

    Total calculated
    $159,521
    From this org
    $139,094
    From related orgs
    $0
    Other
    $20,427
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $139,094
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $20,427
    Filer's total
    $159,521

  • John London

    CHAIRMAN, CO-FOUNDER

    Total calculated
    $0
    Hours/week
    2

  • Eyal Soffer

    TREASURER

    Total calculated
    $0
    Hours/week
    2

  • Channing Stave PhD

    SECRETARY

    Total calculated
    $0
    Hours/week
    2

  • Khalil Barrage

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2

  • Hearn Jay Cho MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2

  • Mark Savoye

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2

  • Michael Niedzielski

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2

  • Julia Roux

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2

  • Diala Tabet

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2

  • Lindy Gad

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Form 990 of other organizations
  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 3
FAIR MARKET VALUE COMPARISON OF SIMILAR ORGANIZATIONS

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

Provenance

Return type
form_990
Tax year
2022
Filed
10 November 2023
IRS schema version
2022v5.0
Source object
202313179349303926

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.